Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023
This study shows a significant shift in the use of first-line glucose-lowering therapies from metformin to GLP-1RAs and SGLT2is. The proportion of first-line GLP-1RA and SGLT2i users with cardiovascular disease, heart failure, or chronic kidney disease has increased significantly over time, aligning with guidelines from the American Diabetes Association. Further studies are merited to evaluate the cost-benefit implications of this shift in first-line glucose-lowering use.
Authors
- Chester B. Good (ORCID: https://orcid.org/0000-0003-4388-4558)
- Duy Ngoc (ORCID: https://orcid.org/0000-0002-7527-9320)
- Tiffany Lee (ORCID: https://orcid.org/0000-0001-5659-9831)
- Samuel K. Peasah (ORCID: https://orcid.org/0000-0002-4991-7392)
- Angela Inneh
- Urvashi Patel
Institutions
- University of Pittsburgh (US)
- UPMC Center for High Value Health Care (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-04-29
- DOI
- https://doi.org/10.18553/jmcp.2025.31.5.520
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47